CELL INTELLIGENCE · 肿瘤细胞治疗研究

Inclusion Criteria:

* Alive, deceased, or unreachable participants (as permitted by local regulation), aged ≥18 years at the start of first-line treatment for BPDCN, and treated with chemotherapy regimens (at a minimum) as first-line treatment for BPDCN from May 2016
* Diagnosed with BPDCN, based on clinical, laboratory, and imaging (where performed per institutional practice) assessments, with a demonstration of a specific immunophenotype (either by immunohistochemistry or flow cytometry), particularly CD4, CD56, and CD123
* Participants (or their legally authorized representatives) who have signed the informed consent and privacy form, where required as per local regulation

Exclusion Criteria:

* Participant has received an investigational agent as first-line therapy for BPDCN
* Participant has received first-line therapy for BPDCN in an interventional clinical trial

主要终点：Objective Response Rate · Baseline through Month 18；Composite Complete Response · Baseline through Month 18；Number of Participants Bridged to Stem Cell Transplant · Baseline through Month 18；Duration of Response · Baseline through Month 18；Real-world Progression-free Survival · Baseline through Month 18；Overall Survival · Baseline through Month 18
次要终点：Time to Next Treatment；Number of Different First-line Treatment Regimens and Sequences Received

• Chemotherapy · Adult participants with BPDCN who have been treated with chemotherapy regimens (at a minimum) as first-line treatment from May 2016.

The main goal of this study is to investigate the effectiveness and safety of chemotherapy agents in the treatment of participants with BPDCN and to provide comparator arm data to the prospective ELZONRIS registry study (STML-401-0521).